Alimera land $30M in third round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Alimera Sciences
|
$30M
|
Existing investors |
Alimera Sciences plans to use much of that money to grab a much bigger share of the future profits expected from its late-stage therapy for diabetic macular edema. |
|
TxCell
|
$16.54M
|
Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure |
TxCell, which develops therapies for autoimmune and chronic inflammatory diseases, will use the funding to progress its development programs on Crohn's disease, rheumatoid arthritis and a number of orphan diseases. |
|
EyeGate
|
$15M
|
Medicis Capital, Ventech, Innoven Partenaires and The Nexus Group |
The company will use the funding to commence two Phase II clinical studies using the EyeGate II Delivery System and it's own formulation of a corticosteroid. |
|
EnGene
|
$6.4M
|
Saad Investments Company |
EnGene, which is developing a treatment for diabetes called GEMS-Insulin, announced today it has raised $6.4 million in a Series A financing. Release |
|
Axial Biotech
|
$6M
|
Johnson & Johnson Development Corporation, vSpring Capital and Ohio Biotech Group |
Axial is advancing new technology in molecular diagnostics and motion preserving to develop a genetic prognostic test for Adolescent Idiopathic Scoliosis. |